PT Darya-Varia Laboratoria Tbk (IDX:DVLA)

Indonesia · Delayed Price · Currency is IDR

1,580.00

-5.00 (-0.32%)

Jun 22, 2026, 10:24 AM WIB

-7.06% (1Y)

Market Cap	1.78T -3.9%
Revenue (ttm)	2.28T +8.7%
Net Income	140.39B -16.2%
EPS	125.35 -16.2%
Shares Out	1.12B
PE Ratio	12.64
Forward PE	n/a
Dividend	108.00 (6.81%)
Ex-Dividend Date	n/a

Volume	4,600
Open	1,600.00
Previous Close	1,585.00
Day's Range	1,580.00 - 1,600.00
52-Week Range	1,450.00 - 1,715.00
Beta	-0.10
Analysts	Hold
Price Target	425.00 (-73.1%)
Earnings Date	Jul 28, 2026

About IDX:DVLA

PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Consumer Health Products, Prescription Drugs, Export & Toll Manufacturing, and Services. The company offers consumer health products, including skin nutrition products under the Natur-E brand; respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brands for nasal congestion, cough, and breathing issues caused by allergy; multivitamins under the Enervon... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1976

Employees 1,351

Stock Exchange Indonesia Stock Exchange

Ticker Symbol DVLA

Full Company Profile

Financial Performance

In 2025, IDX:DVLA's revenue was 2.23 trillion, an increase of 6.90% compared to the previous year's 2.09 trillion. Earnings were 163.95 billion, an increase of 5.00%.

Financial Statements